{
    "nct_id": "NCT03309111",
    "official_title": "A Phase 1, First-in-Human, Multicenter, Open-Label, Two-Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects With Previously Treated Multiple Myeloma",
    "inclusion_criteria": "* Documented diagnosis of multiple myeloma with measurable disease (serum, urine, or free light chain) per International Myeloma Working Group (IMWG) criteria, including non-secretory or oligo-secretory multiple myeloma which has relapsed after or is refractory to prior therapies, including proteasome inhibitors (PIs), immunomodulators (IMiDs) and anti-CD38 targeted therapies (daratumumab, isatuximab).\n* Eastern Cooperative Oncology Group (ECOG) performance-status score of 2 or less and 1 or less (for France).\n* Adequate hematologic, renal, and hepatic functions\n* Seronegative for hepatitis B antigen; positive hepatitis B tests can be further evaluated by confirmatory tests, and if viral load is negative, the subject can be enrolled.\n* Seronegative for hepatitis C antibody; if positive, then further test for the presence of antigen by hepatitis C virus polymerase chain reaction (HCV PCR). If HCV antigen tests are negative, then the subject can be enrolled.\n* Oxygen saturation level ≥92% on room air.\n* Left ventricular ejection fraction (LVEF) ≥50% and no pericardial or pleural effusion at Screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active central nervous system involvement\n* Exposure to daratumumab or isatuximab within 2 months prior to the start of study treatment\n* Active plasma cell leukemia\n* Active infectious disease\n* Clinically significant cardiovascular and respiratory conditions\n* History of HIV infection\n* Subjects requiring prohibited concomitant medications",
    "miscellaneous_criteria": ""
}